ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

Rhea-AI Summary

ARCA biopharma (Nasdaq: ABIO) announced that CFO Jeff Dekker will present at the Q3 Virtual Investor Summit on August 18, 2021, at 1:15 PM ET. The company specializes in genetically targeted therapies for cardiovascular diseases and is developing rNAPc2 for RNA virus-related conditions, with a focus on COVID-19. The drug is in Phase 2b clinical testing and has received Fast Track designation from the FDA. Additionally, ARCA is developing Gencaro (bucindolol hydrochloride) as a treatment for atrial fibrillation in heart failure patients, also with Fast Track designation.

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021.

ARCA is scheduled to present on Wednesday, August 18, 2021 at 1:15 PM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at: https://zoom.us/webinar/register/WN_ERJdeAK7QtKvTBMwC5gpcg .

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2b clinical testing. ARCA is also developing Gencaro^TM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

FAQ

When is ARCA biopharma's presentation at the Q3 Virtual Investor Summit?

ARCA biopharma's presentation is scheduled for August 18, 2021, at 1:15 PM ET.

Who will represent ARCA biopharma at the investor summit?

CFO Jeff Dekker will represent ARCA biopharma at the Q3 Virtual Investor Summit.

What therapies is ARCA biopharma developing?

ARCA biopharma is developing rNAPc2 for COVID-19 and Gencaro for atrial fibrillation in heart failure patients.

What is the development status of rNAPc2?

rNAPc2 is currently in Phase 2b clinical testing and has received Fast Track designation from the FDA.

What is Gencaro's significance in ARCA biopharma's portfolio?

Gencaro is a genetically targeted treatment for atrial fibrillation in heart failure patients and has also received Fast Track designation from the FDA.